Payment overview · 2025
General Payments
$202.10
6 reported records · 5 companies
Healthcare provider profile · identity verified
Sixto Malabanan Lirio, MD
Allopathic & Osteopathic Physicians|Family Medicine · CAPE MAY COURT HOUSE, NJ · NPI 1780683672
Verified facts
What the public records show
CMS Open Payments records show Sixto Malabanan Lirio, MD received $202.10 in general payments during 2025 across 6 reported records.
SK Life Science, Inc. accounted for 56.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Linzess by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$114.51 | 56.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.48 | 15.6% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $21.38 | 10.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.02 | 8.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.71 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.10 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $114.51 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
112 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 37 |
| Levetiracetam | Levetiracetam | 255 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 21 |
| Montelukast Sodium | Montelukast Sodium | 190 | 16 |
| Buspirone Hcl | Buspirone Hcl | 178 | 13 |
| Furosemide | Furosemide | 176 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 28 |
| Divalproex Sodium | Divalproex Sodium | 170 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 25 |
| Potassium Chloride | Potassium Chloride | 164 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 13 |
| Omeprazole | Omeprazole | 157 | 15 |
| Risperidone | Risperidone | 138 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 15 |
| Eliquis | Apixaban | 119 | 21 |
| Finasteride | Finasteride | 117 | suppressed |
| Losartan Potassium | Losartan Potassium | 117 | 18 |
| Linzess | Linaclotide | 112 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 14 |
| Lisinopril | Lisinopril | 111 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 107 | 15 |
| Ciclopirox | Ciclopirox Olamine | 102 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | suppressed |
| Simvastatin | Simvastatin | 89 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 88 | suppressed |
| Famotidine | Famotidine | 88 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 14 |
| Lorazepam | Lorazepam | 84 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 82 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 11 |
| Lamotrigine | Lamotrigine | 78 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 12 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Ramelteon | Ramelteon | 72 | suppressed |
| Gabapentin | Gabapentin | 66 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 65 | suppressed |
| Metformin Hcl | Metformin Hcl | 62 | 12 |
| Sertraline Hcl | Sertraline Hcl | 59 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 58 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 57 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Phenytoin | Phenytoin | 50 | suppressed |
| Lactulose | Lactulose | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 15 |
| Lovastatin | Lovastatin | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Triazolam | Triazolam | 39 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Lacosamide | Lacosamide | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Prolia | Denosumab | 32 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 15 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Xcopri | Cenobamate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 24 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Versacloz | Clozapine | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 15 |
| Cephalexin | Cephalexin | 19 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nayzilam | Midazolam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Secuado | Asenapine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.10 · 6 records | SK Life Science, Inc. | AUSTEDO XR, Fintepla, INGREZZA, UZEDY, VRAYLAR, XCOPRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xcopri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error